Psychable's Co-Founder and Chief Strategy Officer, Matt Zemon, shares details about the company's new "Buy One, Give One" ketamine-assisted therapy program.
Similar Posts
Interview With Carlos Tanner
In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.
A Doctor Explains Ibogaine: A Psychedelic Plant Being Used to Heal Addictions
A Doctor Explains Ibogaine: A Psychedelic Being Used to Heal…
Interview with Julianne Keu, Psychedelic YouTuber
In this episode, YouTuber Julianne Keu discusses how she went from microdosing psilocybin to participating in shamanic doses to explore the mystical and spiritual universe.
How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)
Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.
We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests
MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)
MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own
Meet the Next-Gen Psychedelic Treating Alcoholism | Is this the Future of Addiction Treatment?
In today’s episode of PsycBiz, James —the Psychedelic Investor— sits…
BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study
HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).
This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.
In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.
Timestamps:
0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #CMPS #PsychedelicTherapy